Wolverine Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Wolverine Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-853,416	Closed	-$3.24M	–	1898
2020 Q1	$3.24M	Buy	853,416 +798,647	+1,458%	+$3.44M	0.05%	274
2019 Q4	$278K	Buy	+54,769	New	+$290K	﹤0.01%	906
2015 Q4	–	Sell	-38,108	Closed	-$217K	–	2014
2015 Q3	$217K	Sell	38,108 -92,400	-71%	-$709K	0.01%	889
2015 Q2	$973K	Sell	130,508 -20,200	-13%	-$122K	0.02%	480
2015 Q1	$901K	Buy	150,708 +89,200	+145%	+$561K	0.02%	468
2014 Q4	$465K	Sell	61,508 -101,467	-62%	-$607K	0.01%	683
2014 Q3	$845K	Sell	162,975 -75,392	-32%	-$376K	0.02%	521
2014 Q2	$1.03M	Buy	238,367 +50,400	+27%	+$192K	0.02%	413
2014 Q1	$768K	Buy	+187,967	New	+$961K	0.02%	476

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Wolverine Asset Management's PGNX Position: Q2 2020 in Review

Wolverine Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 853,416 shares — an estimated $3.24M sold.

Wolverine Asset Management first reported a position in PGNX in Q1 2014 and held it in 9 quarters. The position peaked at $3.24M in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Wolverine Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Wolverine Asset Management sold 853,416 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $3.24M.
Wolverine Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 9 quarters.
Wolverine Asset Management's Progenics Pharmaceuticals Inc position peaked at $3.24M in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Wolverine Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.